Bayer reported Phase III REVEAL study results for its investigational PET radiotracer iodine 124 evuzamitide (I 124 evuzamitide) in the diagnosis of cardiac amyloidosis. The study met its primary endpoint (details not included in the excerpt), supporting the clinical validity of the diagnostic. This is likely supportive for sentiment around Bayer’s pipeline but, with limited disclosed metrics, should be a modest price mover.
Bayer reported Phase III REVEAL study results for its investigational PET radiotracer iodine 124 evuzamitide (I 124 evuzamitide) in the diagnosis of cardiac amyloidosis. The study met its primary endpoint (details not included in the excerpt), supporting the clinical validity of the diagnostic. This is likely supportive for sentiment around Bayer’s pipeline but, with limited disclosed metrics, should be a modest price mover.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
